Thursday, February 21, 2013

Q&A: Inovio CEO on DNA Vaccines

Source: The Wall Street Journal

One area of biotechnology that has drawn a lot of attention in recent years is DNA vaccines. Unlike traditional vaccination that uses an infectious agent (such as a weakened version of a virus) to stimulate the immune system, DNA vaccination tries to generate immune responses by injecting genetically engineered DNA molecules into body tissues.

Pennsylvania-based Inovio Pharmaceuticals Inc. INO -4.55% specializes in DNA vaccines. Many of its vaccines – for cancers, leukemia, hepatitis C and other diseases — are in mid-stage clinical testing phases.

Inovio Chief Exeucitive Joseph Kim, who is attending The Wall Street Journal’s Unleashing Innovation conference in Singapore this week, shared his views on the future of DNA vaccines.


For the complete article, click here...
  • Managing Partners

    William Davidson Institute
  • Sponsoring Partner

    Citi Foundation
  • Content Partners


Have an Idea for a Story?Have an Idea for a Story?

Make A Suggestion

Social MediaSocial Media

Facebook Twitter

Story Snapshot